Hypertrophy Clinical Trials 2023

What are the top hospitals conducting hypertrophy research?

In the realm of medical research, hospitals across the United States are making remarkable strides in understanding and treating hypertrophy, a condition characterized by abnormal enlargement of organs or tissues. Leading the charge is Massachusetts General Hospital in Boston, where seven active clinical trials focused on hypertrophy are currently underway. Since their first recorded trial in 2007, this renowned institution has conducted a total of 13 studies dedicated to unraveling the mysteries surrounding this complex condition. Not far behind is Brigham and Women's Hospital also located in Boston. With six ongoing hypertrophy trials and a history of 11 completed studies since initiating their inaugural trial in 2006, they have established themselves as an important player in driving forward progress.

Further westward lies Oregon Health & Science University based in Portland. This institution has thrown itself into tackling hypertrophy with equal vigor through its participation in six active clinical trials for this condition. Though relatively new to the field compared to its counterparts, having launched its first hypertrophy trial only in 2014, it has already contributed significantly with eight all-time trials under its belt.

Meanwhile Yale New Haven Hospital located conveniently at New Haven joins these ranks with five current hypertrophy clinical trials while carrying out nine previous ones after commencing their maiden investigation back until2015.At Washington University School of Medicine situated amidst cultural hub Saint Louis,the battle against hypertrophy takes form through four ongoing investigations joined together with nine previously held experiments; theirs were initiated nearly just one decade ago during2012.

These top hospitals exemplify dedication and expertise when it comes to confronting the challenges posed by hypertrophy head-on. The collective efforts showcased here offer hope for those affected by this debilitating condition while serving as catalysts for future breakthroughs that hold potential to improve countless lives worldwide

Which are the best cities for hypertrophy clinical trials?

When it comes to hypertrophy clinical trials, several cities emerge as leading hubs for research. Boston, Massachusetts takes the top spot with 20 active trials investigating treatments like Mavacamten and CK-3773274 at various dosage levels. New york, New York closely follows with 13 ongoing studies focused on similar interventions. Additionally, New Haven, Connecticut and Portland, Oregon both boast 12 active trials examining the effectiveness of Mavacamten in different contexts. Houston, Texas also plays a significant role in hypertrophy research with 11 ongoing studies exploring potential treatment options. These cities offer individuals experiencing hypertrophy access to cutting-edge clinical trials that pave the way for advancements in care and improved outcomes.

Which are the top treatments for hypertrophy being explored in clinical trials?

Clinical trials are actively exploring various treatments for hypertrophy, aiming to provide effective solutions for this condition. One of the top contenders is mavacamten, which has shown promise in two ongoing trials and has been involved in four clinical trials dedicated to hypertrophy since its introduction in 2020. Another potential treatment option is intervention by a Population Health Coordinator, currently being investigated in one active trial and showing potential based on its inclusion in the all-time list with one relevant trial listed since 2023. These innovative approaches pave the way for advancements that could significantly impact patients dealing with hypertrophy.

What are the most recent clinical trials for hypertrophy?

Exciting advancements are underway in the field of hypertrophy, with recent clinical trials offering new possibilities for treatment and management. One promising study is Cohort 1, a Phase 1 trial that explores innovative approaches to address hypertrophy-related concerns. Additionally, Aficamten (CK-3773274), tested at various dosage levels ranging from 5 mg to 20 mg in a Phase 3 trial, shows potential as an effective intervention for hypertrophy. Another Phase 2 trial called Cohort 1 furthers our understanding of this condition and its treatments. Furthermore, Mavacamten's Phase 3 trial showcases its potential benefits in managing hypertrophy symptoms. Lastly, Yttrium-90 (Y-90) resin microspheres were investigated in a Phase 1 study as a possible therapeutic option for individuals affected by hypertrophy. These recent trials highlight the ongoing efforts to advance medical knowledge and improve outcomes for those living with hypertrophy.

What hypertrophy clinical trials were recently completed?

Recently, two noteworthy clinical trials in the field of hypertrophy have reached completion, shedding light on potential advancements in treatment. In June 2021, Stanford University concluded a trial investigating the efficacy of Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML). Similarly, Cytokinetics completed a trial testing CK-3773274 (10 - 30 mg) in January 2020. These significant milestones highlight ongoing efforts to understand and address hypertrophy-related conditions, offering hope for improved patient outcomes.